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2152males respond differently than females. More than 80
anatomic, chemical, and physiological similarities
between animals deﬁcient in copper and people with
ischemic heart disease have been identiﬁed (4,5).
Perhaps low DHEA in their subjects (1) was a subtle,
indirect sign of copper deﬁciency. People who believe
that high concentrations of DHEA are beneﬁcial may
ﬁnd that copper supplements are less expensive and
less hazardous than DHEA supplements. A supple-
ment containing copper produced improvement in
heart failure.*Leslie M. Klevay, MD, SD in Hyg
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Recognizing Sex
Similarities in
Cardiovascular
Disease ResearchWe read the interesting article by Tivesten et al. (1),
which concluded that low serum dehydroepiandros-
terone (DHEA) and its sulfate predict an increased
risk of coronary heart disease in men. This study
examined a cohort of 2,416 elderly men, and previ-
ously we evaluated DHEA-S in 270 women. In
our National Heart, Lung, and Blood Institute–
Women’s Ischemia Syndrome Evaluation study (2),
we found among postmenopausal women undergoing
coronary angiography for suspected myocardial
ischemia, that lower circulating DHEA-S predicted
higher cardiovascular disease (CVD) mortality and all-
cause mortality, similar to the Tiversten et al.ﬁndings among men. Furthermore, this relationship
was independent of other major CVD risk factors but
was attenuated for presence or severity of angio-
graphic coronary artery disease. Our ﬁndings sug-
gested that DHEA-S levels and CVD mortality could be
mechanistically linked to atherosclerosis.
A large portion of THE Tivesten et al. (1) discussion
focused on possible mechanisms for DHEA/-S to
reduce risk of cardiovascular events and we believe
that our research ﬁndings are an important addition
to support this discussion. Although Tivesten et al. (1)
cited studies that included women, the discussion
only mentioned men, and did not mention our sex-
speciﬁc study (2). It is important that contemporary
research not perseverate the historical “male-
pattern” biomedical model where studies in women
are either ignored, as was the case in the Tivesten
et al. article, or made to ﬁt into male diagnostic and
therapeutic standards (3,4). It is similarly important
to evaluate and demonstrate areas where women and
men have similar ﬁndings, as the Tivesten et al. and
our prior WISE study demonstrate.*Chrisandra Shufelt, MD, MS
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REPLY: Recognizing Sex Similaritiesin Cardiovascular Disease Research
Copper, Coronary Heart Disease,
and DehydroepiandrosteroneAspects of gender and biological sex are important to
address in research, and we thank Dr. Shufelt and
colleagues for their letter. Certainly it would have
been suitable to address the association between de-
hydroepiandrosterone (DHEA), its sulfate, and car-
diovascular risk in women in the discussion of our
paper (1), even if women were not included in
the MrOS cohort. The data by Shufelt et al. (2) are
interesting and suggest an association between low
DHEA-S and cardiovascular risk in women as in men,
whereas other studies have suggested a U-shaped
association in women (3).
We also thank Dr. Klevay for sharing his hypothesis
regarding copper, coronary heart disease, and DHEA,
proposing that low DHEA may be a sign of copper
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Aspirin Treatment and
Outcomes After
Percutaneous Coronary
InterventionResults of the ISAR-ASPI RegistryWe read with great interest the paper by Mayer et al.
(1) demonstrating an association between high
on-aspirin treatment platelet reactivity and cardio-
vascular complications in patients undergoing per-
cutaneous coronary intervention. We would like to
congratulate the investigators for this pivotal study
and suggest that they consider prior aspirin use as
another variable contributing to adverse outcomes. In
fact, we believe that the larger number of patients
with high on-aspirin treatment platelet reactivity in
the ISAR-ASPI (Intracoronary Stenting and Antith-
rombotic Regimen—Aspirin and Platelet Inhibition)
registry compared with other populations using tests
speciﬁc for COX-1 activity (2,3) may be due to the
higher percent of patients receiving aspirin treatment
at the time of hospital admission.
Such consideration follows our demonstration that
human megakaryocytes have an adaptive response to
aspirin, leading to up-regulation of platelet multidrug
resistance protein 4 (MRP4) (4). Aspirin effects are
reduced in patients undergoing coronary artery by-
pass grafting because of platelet MRP4 overex-
pression, because aspirin is an MRP4 substrate.
Moreover, with long-term drug exposure, eukaryotic
cells may trigger speciﬁc genes leading to cellular
mechanisms modulating their effects.
Because MRP4 inhibition reduces collagen-induced
platelet activation, we hypothesized that platelets
with MRP4 overexpression may be hyperresponsive.
A reduction of aspirin-dependent platelet inhibition
over time is well established. In fact, aspirin-treated
healthy volunteers, either at high (1,300 mg/day)
or low (100 mg/day) concentrations, showed reduced
platelet aggregation in the early weeks of treatment,
